• ReflectionBio Receives Orphan Drug Designation from FDA americanpharmaceuticalreview
    August 29, 2018
    Reflection Biotechnologies Limited (ReflectionBio) announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ReflectionBio's RBIO-101 program (AAV.CYP4V2), an AAV-based gene therapy product for treating Bietti's Crystall
PharmaSources Customer Service